Biotech CEO sentenced for $28M fraud scheme

The CEO of biotech company Decision Diagnostics Corp., Keith Berman, was sentenced to seven years in prison for a securities fraud scheme that resulted in about $28 million in investor losses and obstruction of a related U.S. Securities and Exchange Commission investigation.

Advertisement

From February through December 2020, Mr. Berman falsely claimed that Decision Diagnostics created a 15-second test to detect COVID-19 in a finger prick sample of blood. Though the test did not exist, he told investors that the FDA was on the brink of approving it. Mr. Berman also obstructed an SEC investigation into his conduct.

Mr. Berman pleaded guilty to securities fraud, wire fraud and obstruction of an official proceeding.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.